OSAKA, Japan, December, 7, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi presented results from the Japanese Phase 1/2 clinical trial of S-268019, a recombinant protein-based vaccine for COVID-19, caused by the novel coronavirus (SARS-CoV-2), at The 25th Annual Meeting of The Japanese Society for Vaccinology.
โฆษณา
- ดาวน์โหลดแอปพลิเคชัน
- © 2024 Blockdit
